Welcome to our dedicated page for Definitive Healthcare news (Ticker: DH), a resource for investors and traders seeking the latest updates and insights on Definitive Healthcare stock.
Definitive Healthcare Corp. reports developments in healthcare market data, analytics, and commercial intelligence for organizations operating on the business side of healthcare. Its SaaS-based platform and related solutions support use cases such as market selection, go-to-market planning, provider targeting, affiliation analysis, prescription-pattern visibility, Key Opinion Leader identification, and workflow data enrichment.
Recurring news for DH includes quarterly and annual financial results, guidance commentary, customer wins and renewals across life sciences and health-system markets, expansions involving products such as Monocl and Population Intelligence, data-integration use cases, and investor conference presentations. Company updates also describe subscription revenue trends, adjusted profitability measures, cash flow, and commercial execution across new logos and existing customers.
Definitive Healthcare (Nasdaq: DH) has launched a redesigned mobile app for its View Suite platform, aimed at enhancing accessibility to healthcare commercial intelligence. Announced on July 09, 2024, the new DH View Suite mobile app provides sales and marketing teams with instant access to essential data, optimizing their productivity in the field. The app offers detailed profiles of healthcare professionals and organizations, including metrics on clinical performance, finances, and more. Available for download on Apple and Android devices at no additional cost to existing customers, the app ensures that users are always prepared for client meetings and industry events.
On June 25, 2024, Definitive Healthcare (Nasdaq: DH) announced the granting of inducement awards to its new CEO, Kevin Coop. The awards include 1,137,038 performance-based restricted stock units (PSUs) and 1,170,047 time-based restricted stock units (RSUs), effective June 24, 2024. These grants are in accordance with Nasdaq Listing Rule 5635(c)(4) and are a part of the company's 2023 Inducement Plan.
The RSUs will vest in stages, with one-fourth vesting on July 1, 2025, and the rest in 12 equal quarterly installments. The PSUs are divided into four tranches, tied to specific stock price hurdles and performance periods, with vesting subject to the Human Capital Management and Compensation Committee's certification and Mr. Coop's continued service.
Definitive Healthcare (Nasdaq: DH) has been awarded the 2024 Databricks Healthcare and Life Sciences Partner of the Year. This accolade highlights their successful collaboration with Databricks in offering innovative data and AI solutions to the healthcare and life sciences sector.
Leveraging the Databricks Marketplace, Definitive Healthcare provides access to extensive datasets, including prescription claims, behavioral health data, and affiliations intelligence. This aids organizations in understanding patient journeys, prioritizing opportunities, and engaging key medical experts for better healthcare outcomes.
Casey Eastlack, AVP at Definitive Healthcare, expressed pride in the recognition, emphasizing the shared mission to deliver deeper and faster healthcare insights for improved decision-making and innovation. Michael Sanky of Databricks praised the partnership's impact on advancing outcomes for customers in the sector.
Definitive Healthcare (Nasdaq: DH) published its 2023 Sustainability Report, showcasing its achievements in environmental, social, and governance (ESG) practices. Highlights include the retention of an ESG consultant to measure greenhouse gas emissions, and the closure of its least energy-efficient office. On the social front, the company improved diversity at the executive level, contributed 1,940 volunteer hours, and raised over $300,000 in charitable donations. In governance, Definitive Healthcare completed a SOC2 assessment and enhanced its cybersecurity and data privacy framework.
Definitive Healthcare, a leader in healthcare commercial intelligence, announced that Founder, Interim CEO, and Executive Chairman, Jason Krantz, will present at the Stifel 2024 Cross Sector Insight Conference. The presentation is scheduled for June 4, 2024, at 9:10 a.m. ET. A live webcast will be available on the Definitive Healthcare investor relations website, with a replay accessible for a time. The announcement highlights the company's active role in industry events and its ongoing efforts to engage with investors and stakeholders.
Definitive Healthcare (Nasdaq: DH) announced the appointment of Kevin Coop as CEO, effective June 24, 2024. Coop replaces Jason Krantz, who served as Interim CEO and will remain as Executive Chairman. Coop brings over 30 years of experience in operations, product, and revenue growth, including leadership roles at DailyPay, Dun & Bradstreet, Black Knight, and Verisk Analytics. The company aims to leverage Coop's expertise to capitalize on the $10 billion healthcare commercial intelligence market, enhancing growth, innovation, and operational efficiency.
On May 14, 2024, Definitive Healthcare announced that its Founder, Interim CEO, and Executive Chairman, Jason Krantz, will present at the 52nd Annual J.P. Morgan Global Technology, Media and Communications Conference. The presentation is scheduled for May 21, 2024, at 10:10 a.m. Eastern Time. A live webcast of the event will be available on the company's investor relations website, with a replay accessible for a period.
Definitive Healthcare reported a 7% increase in revenue to $63.5 million for the first quarter of fiscal year 2024. The company's adjusted EBITDA and net income also showed positive growth compared to the same period last year. Definitive Healthcare expanded its enterprise customer base and made significant customer wins. The Board of Directors approved a stock repurchase program of up to $20.0 million. The company issued financial guidance for the second quarter and full year 2024.
Summary not available.
Summary not available.